Free Trial

Inventiva (IVA) Competitors

Inventiva logo
$5.53 +0.17 (+3.17%)
Closing price 10/9/2025 04:00 PM Eastern
Extended Trading
$4.82 -0.71 (-12.91%)
As of 07:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IVA vs. BHC, IDYA, BLTE, IBRX, ARQT, RXRX, MESO, IRON, AGIO, and DNLI

Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Bausch Health Cos (BHC), IDEAYA Biosciences (IDYA), Belite Bio (BLTE), ImmunityBio (IBRX), Arcutis Biotherapeutics (ARQT), Recursion Pharmaceuticals (RXRX), Mesoblast (MESO), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

Inventiva vs. Its Competitors

Inventiva (NASDAQ:IVA) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Bausch Health Cos has a net margin of 0.99% compared to Inventiva's net margin of 0.00%. Inventiva's return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company Net Margins Return on Equity Return on Assets
InventivaN/A N/A N/A
Bausch Health Cos 0.99%-852.36%5.25%

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 20.0% of Bausch Health Cos shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Inventiva had 7 more articles in the media than Bausch Health Cos. MarketBeat recorded 10 mentions for Inventiva and 3 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 0.57 beat Inventiva's score of 0.50 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inventiva
1 Very Positive mention(s)
2 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bausch Health Cos
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bausch Health Cos has higher revenue and earnings than Inventiva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inventiva$9.95M53.17-$199.34MN/AN/A
Bausch Health Cos$9.86B0.24-$46M$0.2624.60

Inventiva presently has a consensus price target of $16.14, suggesting a potential upside of 191.91%. Bausch Health Cos has a consensus price target of $9.00, suggesting a potential upside of 40.73%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Bausch Health Cos.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inventiva
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Bausch Health Cos
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Inventiva has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Summary

Inventiva beats Bausch Health Cos on 8 of the 14 factors compared between the two stocks.

Get Inventiva News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IVA vs. The Competition

MetricInventivaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$512.75M$3.36B$6.15B$10.64B
Dividend YieldN/A2.29%5.66%4.69%
P/E RatioN/A21.3485.9927.64
Price / Sales53.17488.26628.97141.97
Price / CashN/A47.1938.3262.20
Price / Book-4.5710.4312.956.79
Net Income-$199.34M-$52.40M$3.30B$275.88M
7 Day Performance-15.31%4.97%3.69%1.84%
1 Month PerformanceN/A17.02%10.68%8.84%
1 Year Performance229.17%34.38%83.35%36.10%

Inventiva Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IVA
Inventiva
3.2903 of 5 stars
$5.53
+3.2%
$16.14
+191.9%
+227.2%$512.75M$9.95M0.00100Analyst Forecast
Gap Down
High Trading Volume
BHC
Bausch Health Cos
4.5985 of 5 stars
$6.48
-3.0%
$9.00
+38.9%
-19.4%$2.47B$9.86B24.9220,700Analyst Forecast
IDYA
IDEAYA Biosciences
4.1372 of 5 stars
$27.49
-0.5%
$43.36
+57.7%
-9.1%$2.42B$7M-7.2580Analyst Forecast
BLTE
Belite Bio
2.6207 of 5 stars
$78.10
+3.3%
$96.00
+22.9%
+42.7%$2.41BN/A-50.3910Positive News
Analyst Forecast
IBRX
ImmunityBio
2.7252 of 5 stars
$2.53
-0.4%
$10.75
+324.9%
-26.5%$2.40B$14.74M-5.27590Positive News
ARQT
Arcutis Biotherapeutics
1.3209 of 5 stars
$19.76
-0.8%
$19.80
+0.2%
+111.3%$2.39B$196.54M-26.35150
RXRX
Recursion Pharmaceuticals
2.1762 of 5 stars
$5.53
+0.7%
$7.25
+31.1%
-3.9%$2.38B$58.84M-3.11400Trending News
Analyst Forecast
Options Volume
MESO
Mesoblast
1.8113 of 5 stars
$17.32
-5.9%
$24.00
+38.6%
+112.5%$2.36B$17.20M0.0080Analyst Forecast
Gap Down
IRON
Disc Medicine
2.4271 of 5 stars
$69.28
+2.2%
$98.30
+41.9%
+51.3%$2.36BN/A-15.5030News Coverage
Positive News
Analyst Forecast
Insider Trade
AGIO
Agios Pharmaceuticals
4.5053 of 5 stars
$40.89
+1.0%
$56.00
+37.0%
+3.8%$2.35B$36.50M3.72390Trending News
Analyst Forecast
Analyst Revision
DNLI
Denali Therapeutics
4.2821 of 5 stars
$15.22
-1.3%
$33.50
+120.1%
-39.0%$2.25BN/A-5.44430Analyst Forecast

Related Companies and Tools


This page (NASDAQ:IVA) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners